Navigation Links
S*BIO's JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission (EC) for the Treatment of Myelofibrosis (MF)
Date:10/18/2010

s grants potential market exclusivity of up to 10 years in the EU.

MF is a serious progressive and chronic condition, whereby scar tissue develops in the bone marrow, resulting in a reduced ability to produce sufficient blood cells. Consequently, more blood cells are made in other organs, such as the liver and spleen, which are not as efficient at blood cell production as the bone marrow.  MF is characterized by an enlarged spleen and progressive anaemia.  Current therapies for MF are mostly palliative in nature and survival rates can be short.  While the actual cause of the disease is unknown, the JAK2 gene has been implicated in the development of this condition.

About S*BIO Pte LtdS*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578 in North America and Europe. S*BIO's SB1317, a novel multikinase inhibitor, is in preclinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital a subsidiary of EDBI (EDB Investments), Aravis Ventures, Mitsui Ventures
'/>"/>

SOURCE S*BIO
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. For the Treatment of Rheumatoid Arthritis, Surveyed European Rheumatologists Expect Well-Established TNF-Alpha Inhibitors to Lose Considerable Patient Share to Newer Agents in This Drug Class
2. For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
3. N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
4. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
5. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
6. FDA: Possible Fracture Risk With High Dose, Long-term Use of Proton Pump Inhibitors
7. Proton Pump Inhibitor DEXILANT(TM) (dexlansoprazole) Now Available in U.S. Pharmacies
8. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
9. Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors
10. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
11. Neurocrine Advances VMAT2 Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... Der Pharmariese Lupin ... eine 100-prozentige Beteiligung am Unternehmen ZAO "Biocom" ... Übernahme dringt Lupin in den russischen Pharmamarkt ... Mrd. RUB im Jahr 2014 zu den ... Health). Seit über einem Jahrzehnt verzeichnet der ...
(Date:7/2/2015)... , Chine, 3 juillet 2015 BGI ... à haut débit de l,ADN situé à ... certification de  l,American College of Pathologists  (Collège des ... à Hong Kong constituent ... génération à recevoir la certification du CAP en ...
(Date:7/2/2015)...  New product launches are critical events for the ... thought leaders about new products, Medical Affairs is one ... a new therapy performs at launch. ... leader Best Practices, LLC, critical aspects of launch support ... early stage thought leader (TL) interaction, successful TL targeting, ...
Breaking Medicine Technology:Lupin übernimmt Biocom aus Russland 2Lupin übernimmt Biocom aus Russland 3BGI obtient la certification du Collège des pathologistes américains (CAP) 2Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2
... ASCO Showed Acceptable Tolerability Profile, ... Low Incidence of Grade 3 and 4 Neuropathy, ... eribulin mesylate (E7389) demonstrated activity in a,heavily pretreated population ... to results of a multi-center Phase II clinical,trial. The ...
... breadth of, collaboration with investigators worldwide to develop new treatments for ... diverse forms of cancer ... bisphosphonate, on relapse rate of patients with early-stage breast cancer, - Four ... first results of RECORD-1 study in renal cell ...
Cached Medicine Technology:Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10
(Date:7/3/2015)... , ... July 03, 2015 , ... ... to healthcare providers, has been retained to lead a national chief nursing ... the top-ranked executive search firms in the healthcare industry, B. E. Smith has ...
(Date:7/3/2015)... Lewisville, TX (PRWEB) , ... July 03, 2015 , ... ... in the United States, named Mariah N. Manzanares, MD as the new Medical Director ... the new facility medical director of our Frisco facility,” said Dr. James M. Muzzarelli, ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... sweetFrog Enterprises, ... Mississippi. The opening is the first sweetFrog store located in Mississippi. The premium frozen ... companies in 2014. , The store, located at 104 Railroad Avenue, New Albany, MS ...
(Date:7/2/2015)... ... 02, 2015 , ... When Walker Parking Consultants specified Kenall ... Minnesota, they knew it would save the university energy and maintenance costs. What ... total energy savings after installation was an impressive 89 percent, which resulted in ...
(Date:7/2/2015)... ... ... As Americans celebrate the Fourth of July outdoors this weekend, local physicians ... July is UV Safety Month, and physicians at American Family Care and AFC Doctors ... Experts say most skin cancers can be found early with regular skin exams. Physicians ...
Breaking Medicine News(10 mins):Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:sweetfrog Opens First Location in Mississippi 2Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:Local Physicians Warn of Holiday Health Hazards 2Health News:Local Physicians Warn of Holiday Health Hazards 3Health News:Local Physicians Warn of Holiday Health Hazards 4
... Canadian study links regular alcohol consumption to six cancers , ... moderate or high amounts of alcohol over the course of ... -- but not all -- kinds of cancer, a new ... Canadian researchers, found that the more men drink, the greater ...
... , , , The poll results ... , , WASHINGTON, Aug. 7 A poll conducted ... planning to take precautions against the H1N1 virus, more than a third of ... , , (Logo: http://www.newscom.c ...
... , , , WHEATON, ... has awarded Marianjoy Rehabilitation Hospital a grant in the amount ... Continuing Care Program, which offers group classes for children with ... to help children gain and improve their motor, sensory, play, ...
... in prevention efforts, , FRIDAY, Aug. 7 (HealthDay News) -- ... of medical errors while in the hospital, a new study ... children hospitalized in 2005 at Seattle Children,s Hospital, nearly two-thirds ... to ensure there were no medical errors. , Parents whose ...
... Primate Research Center, Emory University, believe conventional vaccine strategies ... development of an effective AIDS vaccine. Based on studying ... propose an additional new approach to the AIDS vaccine ... issue of Nature Medicine . Their recommendations outline ...
... new information at 6- and 12-months-old, typically ... adults in their 20,s, according to a study ... Fagan,s "The prediction, from infancy, of adult IQ ... is receiving accolades. Mensa International, Limited,- the international organization ...
Cached Medicine News:Health News:Drinking Moderately or More Ups Men's Cancer Risk 2Health News:Drinking Moderately or More Ups Men's Cancer Risk 3Health News:Red Cross Poll Shows Parents Still Lack H1N1 Information From Schools 2Health News:DuPage Community Foundation Awards $15,000 Grant to Marianjoy Pediatric Continuing Care Program 2Health News:DuPage Community Foundation Awards $15,000 Grant to Marianjoy Pediatric Continuing Care Program 3Health News:When Kids Are Hospitalized, Parents Fret About Errors 2Health News:Yerkes researchers propose ambitious new strategies for AIDS vaccine research 2Health News:Yerkes researchers propose ambitious new strategies for AIDS vaccine research 3Health News:Ability to process information as a baby continues into adulthood 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: